Konruns(SH:603590)2022-08-01 16:00Financial Performance - The basic earnings per share for the first half of 2022 was CNY 0.52, a decrease of 17.46% compared to CNY 0.63 in the same period last year[21]. - The diluted earnings per share also stood at CNY 0.52, reflecting the same percentage decrease of 17.46% year-on-year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 60.60% compared to the previous year[21]. - The weighted average return on net assets was 2.86%, down by 0.50 percentage points from 3.36% in the same period last year[21]. - The company's operating revenue for the first half of the year was ¥371,591,327.67, a decrease of 18.43% compared to ¥455,557,666.78 in the same period last year[23]. - The net profit attributable to shareholders for the reporting period was ¥82,038,066.91, down 17.98% from ¥100,022,515.60 year-on-year[23]. - The net profit after deducting non-recurring gains and losses was ¥34,355,332.24, reflecting a significant decline of 60.60% compared to ¥87,201,380.13 in the previous year[23]. - The company reported a significant decrease in accounts receivable financing by 56.21%, down to ¥4,549,159.52, which is 0.14% of total assets[60]. - The company reported a net loss of approximately ¥46.95 million during the current period, reflecting a significant decrease compared to the previous period[151]. Cash Flow and Assets - The cash flow from operating activities increased compared to the same period last year, mainly due to a reduction in promotional service fees[21]. - The net cash flow from operating activities was ¥66,254,643.36, a notable improvement from a negative cash flow of ¥29,584,739.27 in the previous year[23]. - The company's cash and cash equivalents decreased by 6.30% to ¥561,359,820.33, representing 16.84% of total assets[60]. - The total cash and cash equivalents at the end of the period were ¥558,196,657.13, down from ¥980,979,883.10 at the end of the first half of 2021[143]. - The company reported a decrease in cash received from investment recoveries, totaling ¥189,373,420.33 compared to ¥479,585,264.66 in the first half of 2021[143]. - The company's total assets at the end of the reporting period were ¥3,333,060,355.19, down 1.13% from ¥3,371,320,206.37 at the end of the previous year[23]. - The company's total assets reached CNY 2,883,933,542.20, indicating a stable asset base despite the financial losses[157]. Research and Development - R&D expenses amounted to CNY 81.45 million, representing 21.92% of total revenue, with a significant increase of 50.61% year-on-year[52]. - The company is focusing on innovative drug development, with multiple new multi-target receptor tyrosine kinase inhibitors under research, including KC1036, CX1003, KC-B173, CX1026, and Jin Cao Pian[35][36][37][38][39][40][41][42]. - The company plans to enhance its R&D pipeline by collaborating with renowned domestic and international enterprises and research institutions[70]. - The company is focusing on key oncology drug development projects, aiming for expedited market entry through "pressure management" and increased R&D investment[70]. Market and Product Development - The company's main products include "Suling," a leading hemostatic agent, and "Mige Xi," a unique drug for preventing acute bone loss, both of which have established significant market positions[27][30]. - "Suling" has been widely used in over 2,000 hospitals across 31 provinces, helping millions of patients and saving nearly 100 tons of plasma annually[28]. - The company aims to enhance its market presence and profitability through continuous innovation and high-quality product development[27]. - The company plans to leverage its marketing capabilities to enhance sales of the acquired product "Mi Gai Xi," aiming for rapid business growth in the salmon calcitonin market[69]. Corporate Governance and Compliance - The company did not propose any profit distribution plan or capital reserve transfer to increase share capital for the reporting period[5]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[7]. - The company has not faced any environmental issues or administrative penalties during the reporting period, emphasizing its commitment to green production and sustainable development[82]. - The company has achieved ISO14001 and ISO50001 certifications, enhancing its environmental management and energy management systems[83]. - The company has committed to ensuring that the compensation measures for diluted immediate returns are effectively implemented by linking the remuneration system to the execution of these measures[101]. Strategic Partnerships and Acquisitions - The company has established strategic partnerships with German biotechnology firms and WuXi AppTec to enhance its product pipeline[49]. - The company has made performance commitments for the acquisition of "Mi Gai Xi" assets, with net profits of at least RMB 0.8 billion, 1 billion, and 1.2 billion for the years 2021, 2022, and 2023 respectively, totaling no less than RMB 3 billion over three years[102]. - The company is focusing on strategic mergers and acquisitions to enhance its competitive position in the market[150]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period was 17,241[117]. - The company completed the transfer of 1,994,900 shares to the first phase employee stock ownership plan at a price of 31.54 yuan per share, with a lock-up period of 36 months starting from the transfer date[80]. - The company has a profit forecast and compensation commitment for the period from 2021 to 2023[91]. - The company will announce any share reductions by Mu Ren Investment three trading days in advance, ensuring compliance with public commitments made during the IPO[99]. Financial Statements and Accounting Policies - The financial statements have been prepared based on the going concern assumption, indicating no significant issues affecting the company's ability to continue operations for at least 12 months[173]. - The company’s accounting policies comply with the requirements of the enterprise accounting standards, ensuring a true and complete reflection of its financial status[175]. - The preparation of consolidated financial statements is based on control, including subsidiaries determined by voting rights or contractual arrangements[182].